Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    M. Alexander Otto

    M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.

    News

    Michigan Oncologist Charged in Scheme to Illegally Sell Cancer Drugs

    Author:
    M. Alexander Otto
    Publish date: October 31, 2024

    A physician has been indicted on charges of conspiring to and also taking part in the illegal sale of more than $17 million worth of cancer drugs...

    • Read More

    News

    FDA Approves Lymphir for R/R Cutaneous T-Cell Lymphoma

    Author:
    M. Alexander Otto
    Publish date: August 9, 2024

    The immunotherapy is a reformulation of denileukin diftitox that was initially approved for certain patients with persistent or recurrent...

    • Read More

    News

    What Does Hormone Receptor Mean in BRCA-Associated BC?

    Author:
    M. Alexander Otto
    Publish date: July 29, 2024

    Large international study highlights the impact of hormone receptor status in young women with BRCA-associated breast cancer.

    • Read More

    News

    Circulating Tumor DNA Hints at BC Recurrence Risk

    Author:
    M. Alexander Otto
    Publish date: July 24, 2024

    Despite suggestive results, researchers say it’s too early to use ctDNA for adjuvant decisions in early, high-risk breast cancer.

    • Read More

    News

    ‘Double-Expresser’ DLBCL: Tucidinostat Improved R-CHOP Outcomes

    Author:
    M. Alexander Otto
    Publish date: July 15, 2024

    As of yet, there’s been no improvement in overall survival with tucidinostat in an interim analysis of a Chinese phase 3 trial.

    • Read More

    News

    Subcutaneous Immunotherapy Promises Better Life For Cancer Patients

    Author:
    M. Alexander Otto
    Publish date: March 25, 2024

    A move toward subcutaneous versions of standard biologics means less time in clinic for physicians and patients.

    • Read More

    News

    Lung Cancer Screening Unveils Hidden Health Risks

    Author:
    M. Alexander Otto
    Publish date: March 25, 2024

    An ongoing trial is using lung cancer screening CT scans to also look for signs of impending heart disease in 24,000 Europeans.

    • Read More

    News

    BC axillary dissection may be unnecessary for isolated tumor cells after NAC

    Author:
    M. Alexander Otto
    Publish date: January 12, 2024

    A large study has addressed a key question in breast cancer surgery: what to do when isolated tumor cells are found in sentinel lymph nodes after...

    • Read More

    News

    Nodal Radiation May Make BC Axillary Dissection Unnecessary

    Author:
    M. Alexander Otto
    Publish date: January 3, 2024

    A major trial finds that there’s no need to do both in breast cancer patients with just one or two positive sentinel lymph nodes.

    • Read More

    News

    Lower olanzapine dose just as effective for chemotherapy-induced nausea, vomiting

    Author:
    M. Alexander Otto
    Publish date: December 21, 2023

    A 2.5-mg dose of olanzapine may be just as effective at preventing nausea and vomiting as the standard 10 mg with far less daytime drowsiness.

    • Read More

    News

    Can younger postmenopausal women with low-risk BC skip radiation?

    Author:
    M. Alexander Otto
    Publish date: December 8, 2023

    Early results look promising for skipping radiation for low-risk, hormone receptor–positive breast cancer in women 50 years and older, but there...

    • Read More

    News

    Even with insurance, cancer out-of-pocket costs can be punishing

    Author:
    M. Alexander Otto
    Publish date: December 5, 2023

    In a review of commercial claims data, out-of-pocket costs ranged up to $450,374 for stage I breast cancer within a year of diagnosis.

    • Read More

    News

    Omitting surgery may be safe in early BC after neoadjuvant pCR

    Author:
    M. Alexander Otto
    Publish date: November 2, 2023

    A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete...

    • Read More

    News

    Later-line tisotumab vedotin shows survival benefit in metastatic cervical CA

    Author:
    M. Alexander Otto
    Publish date: November 1, 2023

    Results are similar to cemiplimab, but unlike TV, cemiplimab is not yet approved for the indication.

    • Read More

    News

    Induction chemotherapy in first line improves survival for locally advanced cervical cancer

    Author:
    M. Alexander Otto
    Publish date: October 26, 2023

    With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery